If you could vote on Brexit now which option would you choose?
   

The Covid-19 vaccine market is getting crowded — as demand begins to wane


CureVac, a pioneer in the effort to use messenger RNA as a vaccine platform, and its partner, GSK, saw the writing on the wall last fall. When CureVac’s Covid-19 mRNA vaccine candidate underwhelmed in a Phase 2b/3 trial, the pair shifted plans. Too many other vaccines had already proven superior and been cleared by regulators. Rather than spend months tweaking a candidate that would end up battling for a rapidly shrinking share of the Covid vaccine market, they would focus instead on a second-generation product. Soon, other would-be Covid vaccine manufacturers are set to confront the same kinds of hard reality. With two new players — Novavax and a Sanofi-GSK partnership — making or about to make their way into the already crowded global Covid vaccine market, the prospects for those still struggling to prove their vaccines are protective are becoming ever slimmer.

STAT News - March 21, 2022

View the full story here: https://www.statnews.com/2022/03/21/the-covid-19-vaccine-market-is-getting-crowded-as-demand-begins-to-wane/